Review Article

The Neuroscience of Nonpharmacological Traditional Chinese Therapy (NTCT) for Major Depressive Disorder: A Systematic Review and Meta-Analysis

Jiajia Ye¹, Wai Ming Cheung², and Hector Wing Hong Tsang¹

¹Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hunghom, Hong Kong ²Faculty of Education, The University of Hong Kong, Pokfulam, Hong Kong

Correspondence should be addressed to Hector Wing Hong Tsang; hector.tsang@polyu.edu.hk

Received 6 January 2019; Revised 18 April 2019; Accepted 5 May 2019; Published 15 May 2019

Academic Editor: Kevin Chen

Copyright © 2019 Jiajia Ye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Depression is a common disease affecting a large number of people across the world. Many researchers have focused on treatment for depression based on Western scientific approaches, but research based on traditional Chinese medicine (TCM) interventions, studying its clinical effectiveness and the underlying mechanisms involved, has been limited. The aim of this review is to conduct a pioneering systematic review with meta-analysis of existing studies that investigate the neuroscience basis of nonpharmacological traditional Chinese therapy (NTCT). Methods. Both English (Pubmed, Embase, Scopus, SPORTDiscus, PsycINFO) and Chinese (China National Knowledge Infrastructure (CNKI)) databases were searched from inception to October 2018. The effects of NTCT on major depressive disorder, brain activity, and neurophysiological biomarker related outcomes were extracted. Study quality was assessed using the Physiotherapy Evidence Database (PEDro) scale. The effect size of each study was reported by the mean difference of change scores. Results. Six of twelve eligible studies showed that there was a significant improvement in favor of acupuncture in depressive symptoms (SMD -0.69, 95% CI -1.09 to -0.28, p=0.002, $I^2 = 73\%$, p < 0.0008). Based on the available evidence, NTCT including acupuncture, Qigong, and Tai Chi was found to possibly improve brain metabolites, brain activity, and immune and endocrine systems in patients with major depressive disorder. Conclusions. Acupuncture could effectively relieve depressive syndromes. The clinical effects of acupuncture might be attributable to their influence on three proposed pathways, namely, the hypothalamic-pituitary-adrenal (HPA) axis, the locus coeruleus (LC)immunity pathway, and the negative feedback loop of the hippocampus. Nevertheless, conclusions are limited due to the small number of studies included and the low-quality of the study designs. In the future, a cross-sectional study is needed to test the proposed plausible pathways. PROSPERO registration number is CRD42017080937.

1. Introduction

Major depressive disorder (MDD) is a common but serious mental illness. The prevalent fast and furious life and work rhythm is associated with an increase in this mental illness, and it is projected to be the second greatest cause of disability worldwide by 2020 [1, 2]. Furthermore, it affects more than 350 million people, especially those who reside in industrialized and urban areas. The incidence rate of MDD is around 6% in the general population [3], with a lifetime percentage reaching 16% [4, 5]. Symptoms of MDD vary from fatigue, depressed mood, emotional disturbance, poor appetite, sleeping problems, cognitive impairment, and feelings of worthlessness or excessive guilt to suicidal thoughts. Individuals with MDD who experience these symptoms have a reduced quality of life; in addition, it places a heavy economic burden on their families and society [6]. Thus, MDD has currently been targeted as one of the most serious health issues faced by industrialized societies and requiring more urgent attention.

In the past two decades, antidepressant medication (e.g., selective serotonin reuptake inhibitors (SSRIs)) has been used for MDD as a mainstream treatment [7]. Significant effects on reducing levels of depression are widely accepted, but

Beyond this medication, cognitive behavioral therapy (CBT) and counseling are alternative methods for treating MDD [8]. It is worth noting that these nonpharmacological treatments are costly, time-intensive, and not suitable for all individuals with MDD [9–11]. Given this fact, it is necessary to explore other methods for treating MDD like nonpharmacological traditional Chinese therapy (NTCT).

NTCT originated in ancient China and has a long history spanning thousands of years [12]. Mind-body therapies like Tai Chi, Qigong, and acupuncture are core parts of NTCT, which emphasize the integration of mind (brain) and body in practice. In recent years, there has been an increasing worldwide interest in the clinical application of NTCT treating depression, and beneficial effects have been observed in some studies [13, 14]. Beyond this, imaging studies have investigated the potential neuromechanism of beneficial effects of NTCT for MDD [15, 16]. To date, no systematic review has been undertaken to synthesize the existing literature on this topic. Thus, the aim of this review is to summarize the neural basis for the clinical evidence of the effectiveness of NTCT in patients with MDD and to gain a better understanding of the pathological pathways of depression based on NTCT.

2. Methods

This systematic review has been registered on the international prospective register of systematic reviews by the authors (PROSPERO registration number CRD42017080937).

2.1. Information Sources. This systematic review with metaanalysis has been conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Two independent reviewers (Ye and Cheung) served as the systematic reviewers of the following databases: *Pubmed, Embase, China National Knowledge Infrastructure (CNKI), SPORTDiscus, Scopus,* and *PsycINFO,* from their inception to October 2018. The following main keywords were used in the systematic search: depression, major depressive disorder, affective disorder, neuroscience, neuroimag*, neurotransmitter, complementary therapies, traditional Chinese, mind-body therapies, and Qigong (see the appendix). The reference sections of relevant articles were also reviewed by the authors. Languages were restricted to English and Chinese.

2.2. Study Selection and Eligibility Criteria. The titles and abstracts of all the articles obtained through the search were independently screened by the two researchers. Studies were included if they (1) focused on a kind of NTCT (e.g., acupuncture, acupressure, auricular therapy, massage, Qigong, moxibustion, and Tai Chi); (2) involved patients diagnosed as MDD based on any valid and clinical diagnostic criteria [17]; (3) recruited adults (aged above 18); (4) had a control group; (5) targeted outcomes using depression

scales with at least one neuroscience measurement including electroencephalography (EEG), functional magnetic resonance imaging (fMRI), magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and functional nearinfrared spectroscopy (fNIRS) but were not limited to biomarkers such as blood, saliva, and urine samples; (6) were full papers written in English or Chinese; and (7) were published in peer-reviewed journals. Studies were excluded if (1) the full text was not available; (2) they had a focus on children (under the age of 18); (3) they had a focus on pharmacological treatments; (4) they used outcome measures without depression scales and neuroscience assessments; and (5) they were literature or systematic reviews. Any disagreement between the reviewers was resolved by discussion under the supervision of the corresponding author who is an experienced and seasoned researcher in integrative medicine.

2.3. Data Extraction and Management. Data extraction from selected studies included the characteristics of the population, diagnoses, interventions, study design, and outcomes. Consensus was reached via a discussion if there were disagreements between the two reviewers.

2.4. Study Quality Assessment. The 11-item PEDro scale was used to measure the methodological quality of the clinical studies [18, 19]. It involved eligibility criteria, randomization, concealed allocation, similar baseline, blinding of participants, blinding of therapists, blinding of assessors, key outcome measures from more than 85% of the subjects, intention-to-treat, between group difference, and both point measures and measures of variability. The maximum total score was ten because the first item (eligibility criteria) did not contribute to the total score. Points were awarded when a criterion was clearly satisfied [20].

2.5. Data Analysis. Meta-analysis was conducted through Review Manager (version 5.3, the Nordic Cochrane Centre, Copenhagen, Denmark) on depressive outcomes. The mean changes of the depressive outcomes between the baseline and posttreatment measurements were computed for both the experimental and control groups in eligible studies. The effect size of each study was reported by the mean differences of change scores. When the 95% confidence interval (CI) did not include 0 or the *p*-value was less than 0.05, the CI and statistical significance were reported. The standardized weighted mean difference (SMD) method was performed to obtain the pooled estimates of effect size for studies that reported the same outcome by different scales. The homogeneity of included studies was assessed by the Chisquared (I^2) test. The publication bias was assessed by funnel plot, along with the Egger's Regression Test.

3. Results

3.1. Search Selection. Both electronic and manual searches resulted in 1522 records in total. Forty-three full-text articles were obtained using the predetermined selection criteria,




FIGURE 1: PRISMA flow chart of study selection process.

generating 12 articles with 894 participants. A total of eight articles were finally selected for the meta-analysis. The detailed process for article selection is shown in Figure 1.

3.2. Study Characteristics. There were 265 male and 597 female participants with an age range of 31.80 years to 80.65 years. The range of sample size in these studies was from 36 to 125. The places of publication were mainly in mainland China (n=6, 50%) [15, 16, 21–24], three studies were published in Hong Kong [25–27], and an additional three studies were published in Canada [28], Mexico [29], and USA [30], respectively. Nine of the 12 trials were published in English-language journals, and three of them were published in Chinese-language journals. Nine of these selected articles reported using a randomized control study (RCT) design and three of them used a clinical control trial (CCT) design. Table 1 summarizes the details of the included studies.

The duration of the NTCT varied from six to 12 weeks. Of the trials, only two used follow-up assessment at eight weeks and four weeks [30, 31]. The major intervention in selected trials was acupuncture (n=9). Seven of nine acupuncture trials mentioned that the duration of the intervention was six weeks [21–24, 26, 28, 29], and two of them reported that it was eight weeks [15, 16]. Only three studies reported using Tai Chi and Qigong as an intervention [25, 30, 31]. There were studies measuring the effects of NTCT on depressive syndromes (n=12) [15, 16, 24–26, 28–31], cortisol (n=2) [27, 29], 5-HT (n=3) [21, 24, 27], G-protein (n=1) [26], cytokine (n=3) [21, 22, 28], brain functional connectivity (n=2) [15, 16], brain activity (n=1) [25], CRP (n=1) [30], and HRV (n=1) [23]. Three trials found that in the acupuncture- and Tai Chi-medication groups, the side effects caused by medication were significantly reduced [21, 24, 30]. None of them reported any serious adverse events.

3.3. Quality Assessment of the Studies. As rated by the PEDro scale, the sum scores of the selected trials ranged from 5 to 8, suggesting fair-to-high study quality. It was noted that allocation concealment was not used in three-quarters of the eligible studies [15, 16, 22–24, 26–29]. More than half of the selected studies did not explicitly indicate the blinding of assessors, therapists, or participants [15, 16, 21–24, 26, 29–31] or intention-to-treatment technique [15, 16, 21, 23, 25, 28, 29]. Study quality of all eligible trials is presented in Table 2.

	ent Depression Assessment on diagnostic criteria	HAMD G protein in g 6w DSM-IV platelets G ai G ai G aq	GDS sion, 3 DSM-IV 5-HT 12w Cortisol (salivary)	w CCMD-3 HAMD 5-HT	kly + ily, DSM-IV HRSD dually DSM-IV CRP ,10w	PDS via BDI-II EEG (frontal α sion, DSM-IV asymmetry) essions DSM-IV Hemispheric θ aily coherence (inter/intra)
	Treatment duration	Con1: daily, 6w Con2: daily, 6w	45min/ session, 3 times/w, 12w	daily, 6w	2 hrs/weekly + 10mg/daily, intensity gradually increased, 10w	Conl: 90min/session, weekly, 10 sessions Con2: daily
included studies.	Control group	Conl (n=30): fluoxetine Con2 (n=30): Sham acupuncture + placebo Con3 (n=30): No intervention (health control)	Con (n=17): Newspaper reading	Con (n=48): Western medicine	Con (n=37): Health education + Escitalopram	Conl (n=17): CBT+ medication, Con2(n=16): Medication
TABLE 1: Characteristics of included studies.	Treatment duration	Acupuncture 45min/ Weekday, 6w	Eight Section Broads 45min/ session, 3 times/w, 12w	Acupuncture: 4-5 times/w + Chinese herbs daily, 6w	Tai chi 2hrs/weekly + 10mg/daily, intensity gradually increased, 10w	DMBI 90min/session, weekly, 10 sessions
Tab	Intervention group	N=30 Acupuncture + Fluoxetine	N=21, Eight Section Broads	N=48 Acupuncture + Chinese herbs	N=36 Tai chi + Escitalopram	N=17 DMB1+ medication,
	No. of participants	120	38	96	73	50
	Study design	CCT	RCT	CCT	RCT	RCT
	Source	Song et al., 2007	Tsang et al, 2013	Lian et al, 2017	Lavretsky et al, 2011	Chan et al, 2013

4

	Assessment	HRSD IL-Iß TNF-a IFN-A IL-4 IL-10	CRS SCL-90 Cortisol (salivary)	MADRS SDS fMRI rsFC
	Depression diagnostic criteria	NI-MSQ	NI-MSQ	ICD-10
	Treatment duration	Conl: 20mg/daily +Acupuncture 45min/session, 3 times/w, 6w Con2: Acupuncture 3 times/w + 20mg/daily, 6w	30min/session, twice/w, 6 w	20min/session for first 3 days, 3 days/session for the rest of 8 weeks, +20mg/daily, 8w
nued.	Control group	Con1(n=32): Fluoxetine + sham electro- acupuncture Con2 (n=32): sham electro- acupuncture + placebo capsules Con3 (n=30): No intervention (health control)	Con (n=19): Sham electro- acupuncture with low frequency (4Hz) Non-therapeutic point	Con (n=18): Sham acupuncture + fluoxetine The same acupoints (no needle inserted)
TABLE 1: Continued	Treatment duration	Acupuncture 45min/session, 3 times/w + 20mg/daily, 6 w	Acupuncture 30min/session, twice/w, 6 w	Acupuncture 20min/session for first 3 days, 3 days/session for the rest of 8w, +20mg/daily, 8 w
	Intervention group	N=31 Electro- acupuncture + placebo capsules	N=23 Electro- acupuncture with low frequency (4Hz)	N=18 Acupuncture + fluoxetine
	No. of participants	125	42	36
	Study design	CCT	RCT	RCT
	Source	Song et al, 2009	Vazquez et al, 2011	Wang et al, 2016

Evidence-Based Complementary and Alternative Medicine

Study d	esion	No. of	Intervention oroun	TABLE 1: Continued. Treatment	nued. Control group	Treatment	Depression	Assessment
ouu) uoigu par	par	participants	THE ACTIVITY BLOCK	duration Acupuncture 20min/session for	Con (n=18): Con sciningture	duration 20min/session for	diagnostic criteria	MADDS
RCT		36	N=18 Acupuncture + fluoxetine	first 3 days, 3 days/session for the rest of 8w, +20mg/daily, 8 w	+ fluoxetine + fluoxetine The same acupoints (no needle inserted)	first 3 days, 3 days/session for the rest of 8w, +20mg/daily, 8w	ICD-10	fMRI rsFC
RCT		120	N=60 Acupuncture + medication	Acupuncture 30min/session, alternate day, + 20-50mg, 1-2 times/daily, intensity gradually increased, 6w	Con (n=60): Medication	20-50mg, I-2 times/daily, intensity gradually increased, 6w	ICD-10	MADRS 5-HT IL-lß IL-6 IL-4 IL-10
RCT		65	N=33 Acupuncture + SSRIs	Acupuncture 30min/session, 5 times/w + daily SSRIs, 6w	Con (n=32): Western medicine	daily, 6w	CCMD-3	HAMD HRV SDNN HF LF
RCT		61	N=30 Acupuncture +SSRIs	Acupuncture 30min/session, 5 times/w + daily SSRIs, 6w	Con (n=31): Western medicine	daily, 6w	CCMD-3	HAMD IL-6 TNF- α
ntrol group; SSRI: selecti istical Manual of Mental 1; MADRS: Montgomery ctional magnetic resonan ychiatric symptom check	selecti Mental omery esonan t check	ve serotonir Disorders, -Asberg dep (ce imaging; List; HRV: h	Abbreviations. Con: control group; SSRI: selective serotonin reuptake inhibitors; HAMD: Hamilton depression rating scale; GDS: geriatric depression scale; HRSD: Hamilton ratin IV: Diagnostic and Statistical Manual of Mental Disorders, 4th version; CCMD: Chinese Classification of Mental Disorders; ICD-10: the International Classification of Diseases, J protein; 5-HT: serotonin; MADRS: Montgomery-Asberg depression rating scale; SDS: self-rating depression scale; IL: interleukin; TNF- <i>α</i> : tumor necrosis factor- <i>α</i> ; IFN- <i>λ</i> : interferon- <i>λ</i> ; connectivity; fMRI: functional magnetic resonance imaging; DMBI: Dejian mind-body intervention; CBT: cognitive behavioral therapy; PDS: percentage of subjects reducing depressi rating scale; SCL-90: psychiatric symptom checklist; HRV: heart rate variability; SDNN: standard deviation of normal to normal R-R intervals; HF: high frequency; LF: low frequency.	ID: Hamilton depressio ese Classification of Me If-rating depression scal intervention; CBT: cogn : standard deviation of n	n rating scale; GDS: geria intal Disorders; ICD-10: th e; IL: interleukin; TNF-α:1 itive behavioral therapy; P iormal to normal R-R inter	tric depression scale; HH he International Classific tumor necrosis factor-α;] DS: percentage of subject rvals; HF: high frequency	Abbreviations. Con: control group; SSRI: selective serotonin reuptake inhibitors; HAMD: Hamilton depression rating scale; GDS: geriatric depression scale; HRSD: Hamilton rating scale for depression; DSM- IV: Diagnostic and Statistical Manual of Mental Disorders, 4th version; CCMD: Chinese Classification of Mental Disorders; ICD-10: the International Classification of Diseases, 10th revision; CRP: C reactive protein; 5-HT: serotonin; MADRS: Montgomery-Asberg depression rating scale; SDS: self-rating depression scale; IL: interleukin; TNF- <i>a</i> : tumor necrosis factor- <i>a</i> ; IFN- <i>A</i> : interferon- <i>A</i> ; rsFC: resting-state functional connectivity; fMRI: functional magnetic resonance imaging; DMBI: Dejian mind-body intervention; CBT: cognitive behavioral therapy; PDS: percentage of subjects reducing depressive syndrome; CRS: the Carroll rating scale; SCL-90: psychiatric symptom checklist; HRV: heart rate variability; SDNN: standard deviation of normal to normal R-R intervals; HF: high frequency; LF: low frequency.	for depression; DSM- ision; CRP: C reactive esting-state functional ome; CRS: the Carroll

Evidence-Based Complementary and Alternative Medicine

Source	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Item 9	Item 10	PEDro
Song et al, 2007	1	0	1	0	0	1	1	1	1	1	7/10
Tsang et al, 2013	1	0	1	0	0	1	1	1	1	1	7/10
Lian et al, 2017	0	0	1	0	0	0	1	1	1	1	5/10
Lavretsky et al, 2011	1	1	1	1	0	1	0	1	1	1	8/10
Chan et al, 2013	1	1	1	1	1	1	0	0	1	1	8/10
Song et al, 2009	1	0	1	1	1	1	1	0	1	1	8/10
Vazquez et al, 2011	1	0	1	0	0	0	1	0	1	1	5/10
Wang et al, 2016	1	0	1	1	0	0	0	0	1	1	510
Wang et al, 2017	1	0	1	1	0	0	0	0	1	1	5/10
Liu et al, 2015	1	1	1	0	0	0	1	0	1	1	6/10
Zhu et al, 2018	1	0	1	0	0	1	1	0	1	1	6/10
Zhu et al, 2017	1	0	1	0	0	0	1	1	1	1	6/10

TABLE 2: PEDro quality scale.

Note. Item 1: randomization; Item 2: concealed allocation; Item 3: similar baseline; Item 4: blinding of participants; Item 5: blinding of therapists; Item 6: blinding of assessors; Item 7: key outcome measures from more than 85% of subjects; Item 8: intention-to-treat; Item 9: between group difference; Item 10: point measures and measures of variability; 1: explicitly described and present in details; 0: absent, inadequately described, or unclear.

3.4. The Effects of Acupuncture. Indicators of outcome variables in the eligible studies included the Hamilton rating scale for depression (HRSD/HAMD), the Montgomery–Åsberg depression rating scale (MADRS), the Carroll rating scale for depression (CRS), and the self-rating depression scale (SDS). The most used depressive scale in these studies was the HRSD/HAMD (n=5) [22–24, 26, 28]. Two trials that estimated the effects of acupuncture on MADRS were included [15, 21].

We did not include one study in our meta-analysis because of a problem with dependent samples [16]. To detect the consistency of effects of acupuncture interventions on depressive syndromes, a sensitivity analysis was conducted by removing two trials with outlying effect sizes (SMD = -4.05, SMD = -2.35) [24, 29] based on the funnel plot and the Egger's Regression Test (intercept = -10.333, p=0.09) (Figure 2). After removing the outliers for further analysis, no significant difference was found using the Egger's Regression Test (intercept = -2.144, p= 0.67).

A total of six studies were included in this meta-analysis [15, 21–23, 26, 28]. A significant improvement was found in reducing depressive symptoms (*SMD* -0.69, 95% *CI* -1.09 to -0.28, p=0.002, I^2 = 73%, p< 0.0008; Figure 3) with the measurement of depression scales compared to the medication group over time after the acupuncture-medication intervention.

Three trials investigated the treatment effects using the measurement of serotonin (5-HT) [21, 24, 31], and two

of them showed significant benefits in the acupuncturemedication intervention group compared to the medication control group [21, 24]. A study by Song et al. [26] suggested that the intensity of the G α protein in depressive patients was higher than in the healthy controls, but no significant changes were found after acupuncture treatment even if the severity was considerably relieved. Vazquez et al. [29] reported a significant improvement of cortisol level, standard deviation of normal to normal R-R intervals (SDNN), and high frequency (HF) in the acupuncture-medication group, whereas a reduction of low frequency (LF) in the same group was also found [23].

Three trials reported the concentration of cytokines regarding interleukin-Iß (IL-Iß), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-6 (IL-6), interferon- λ (IFN- λ), and tumor necrosis factor- α (TNF- α) [21, 22, 28]. Two trials suggested that IL-6 increased after six weeks of an acupuncture-medication intervention compared to the medication group [21, 22]. One trial reported an increase in concentration of TNF- α [28], while another study showed a contradictory result, suggesting a decreased concentration of TNF- α after six weeks of an acupuncture-medication intervention [22]. There was no change in IL-4 and IL-10 after the six-week intervention [21, 28]. The details of outcomes are summarized in Tables 1 and 3.

Two out of nine trials involved neuroimaging outcomes based on acupuncture techniques. Wang et al. 2017 [16] compared the changes of the resting-state functional connectivity

	5-HT	5-HT Ga protein Cortisol	Cortisol	C reactive protein	$\text{TNF-}\alpha$	IL-lß	TNF- α IL-I β IFN- λ IL-4 IL-10 IL-6 EEG	IL-4	IL-10	IL -6		Neuroimaging outcome	HRV
Song et al., 2007		v		4									
Tsang et al, 2013	Λ		Λ										
Lian et al, 2017	Λ												
Lavretsky et al, 2011				Λ									
Chan et al, 2013											Λ		
Song et al, 2009					Λ	Λ	Λ	Λ	Λ				
Vazquez et al, 2011			Λ										
Wang et al, 2016												Λ	
Wang et al, 2017												Λ	
Liu et al, 2015	Λ					Λ		Λ	Λ	Λ			
Zhu et al, 2018													Λ
Zhu et al, 2017					Λ					Λ			

TABLE 3: Summary of neurophysiological outcomes.




FIGURE 2: Funnel plot of publication bias for depressive syndromes.

(rsFC) in the ventral and dorsal striatal areas with the cortical cortices as well as the striatum seeds and the occipital regions between real and sham acupuncture groups. A significant increase was found after an eight-week intervention. Another study by Wang et al. 2016 [15] emphasized the increased rsFC between the left amygdala and the subgenual anterior cingulate cortex (sgACC)/pregenual anterior cingulate cortex (pgACC), and the right amygdala and left parahippocampus (Para)/putamen (Pu) (Tables 1 and 3).

3.5. The Effects of Tai Chi and Qigong. The indicator of depressive outcome variables from two of three trials was HRSD [27, 30], while another trial measured the change in numbers of MDD patients in each group via the BDI-II scale [25]. All the studies suggested a significant improvement in depressive syndromes in patients with MDD after Tai Chi and Qigong interventions.

Lavretsky et al. [30] showed a reduction in C reactive protein (CRP) after Tai Chi exercise compared to the health education group. Tsang et al. [31] found no statistical difference in cortisol levels after Baduanjin exercise compared to the newspaper reading group. Chan et al. [25] demonstrated that the Chan based-Dejian mind-body intervention (DMBI) significantly improved the frontal α asymmetry, and intraand interhemispheric θ coherence in front-posterior and posterior brain regions. However, these positive findings were not found in either cognitive behavior therapy or waitlist groups.

4. Discussion

TCM has been practiced for over two thousand years. It is important to report the effects of NTCT and propose possible mechanisms that may help to strengthen the scientific basis of TCM. Considering the different ways of approaching diseases, we did not include studies using traditional Chinese herbs in this review. We searched empirical studies published in both English and Chinese language because, traditionally, TCM was performed in ancient China.

This is the first systematic review and meta-analysis synthesizing the effects of NTCT on MDD. We found that acupuncture may have positive effects on the treatment of MDD. This finding suggests that mixed intervention approaches may be the optimal method for the treatment of MDD. However, the evidence on whether this intervention is effective in cytokines, brain connectivity, brain structure, endocrine, HRV, and neurotransmitters is insufficient. As the three studies which mentioned their interventions were mainly based on Tai Chi and Qigong, we may not have sufficient evidence to propose plausible pathways based on mind-body exercise in the current review.

Although previous studies suggested that patients with MDD might benefit from acupuncture interventions [32, 33], the potential mechanism by which acupuncture works on MDD remains elusive. There are three plausible pathological mechanisms that may explain how the body responds to acupuncture interventions in patients with depression. First, the feedback from the hypothalamic-pituitary-adrenal axis (HPA axis) could be considered as the most important mechanism. The activity of the HPA axis is mainly related to the operation of the corticotrophin releasing hormone (CRH) from the parvocellular neurons of the paraventricular nucleus of the hypothalamus [34]. The secretion of CRH stimulates the release of the adrenocorticotropic hormone (ACTH), and the increased level of ACTH stimulates the release of glucocorticoid by the adrenal cortex, leading to an increase in concentration of cortisol. It has been widely suggested that the increased cortisol level is closely related to the severity of depressive symptoms [35–37]. Available evidence suggests that there will be a drop in the level of cortisol in patients with depression after acupuncture intervention. Thus, the dysregulation of the HPA axis can be considered as a central pathophysiological process caused by depression [38, 39].

Second, the locus coeruleus (LC) and immunity pathway would be one of the pathological reasons for depression [40]. LC is the center for synthetizing the adrenergic nerve. The ascending fibers of the adrenergic nerve are mainly projected to the amygdala, hippocampus, and limbic cortex, which are responsible for emotional changes, memory, and behavior changes. The descending fibers of the adrenergic nerve are mainly projected to the lateral dorsal horn of the spinal cord, which corresponds to the regulation of activity of the sympathetic nerve and secretion of catecholamines including epinephrine (N) and norepinephrine (NE). It has been suggested that an activated amygdala may stimulate the release of the corticotrophin-releasing hormone (CRH) that increases the activity of the sympathetic nerve via the mediating lateral dorsal horn of the spinal cord. Once the sympathetic nerve is activated, adrenaline medulla will release NE and E due to the activated adrenal gland. Thus, there is a positive bidirectional feedback loop between the CRH and the sympathetic nerve [39, 41].

Furthermore, the characteristics of the inflammatory responses are based on a complex interaction between proand anti-inflammatory cytokines. NE and E modulate the release of pro- and anti-inflammatory cytokines through α - and β -adrenoceptors [42]. It has been reported that the positive relationship between NE and TNF has been found, and both catecholamines of NE and E stimulated the release of IL-6 via immune cells [43–45]. When a stressful situation happens, adrenergic agents may increase due to the activation of the sympathetic nerve. This may lead to an increase of proinflammatory cytokines such as TNF, IL-1ß, and IL-6 [46]. The positive association between MDD

	Acupunctu	re + Medic	ation	Mee	licatio	n	5	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Liu et al 2015	11	3	60	15	5	60	19.3%	-0.96 [-1.34, -0.59]	
Song et al 2007	12	6.7	30	12.4	7.2	30	17.0%	-0.06 [-0.56, 0.45]	+
Song et al 2009	10.19	5.88	31	11.34	6.62	32	17.2%	-0.18 [-0.68, 0.31]	+
Wang et al 2016	5.44	5.37	18	14.06	4.39	18	12.5%	-1.72 [-2.50, -0.94]	-
Zhu et al 2017	18.3	2.6	30	20.3	2.6	31	16.8%	-0.76 [-1.28, -0.24]	+
Zhu et al 2018	18.5	2.6	33	20.3	2.5	32	17.1%	-0.70 [-1.20, -0.20]	
Total (95% CI)			202			203	100.0%	-0.69 [-1.09, -0.28]	•
Heterogeneity: Tau² = Test for overall effect:			5 (P = 0.0	002); I² =	: 73%			· · · -	-10 -5 0 5 10 Favours Acu+Med Favours Med

FIGURE 3: Effects of acupuncture intervention on depressive syndromes.




FIGURE 4: The neurological pathways associated with HPA axis, LC-immunity, and negative feedback loop of hippocampus.

and proinflammatory cytokines and the negative relationship between anti-inflammatory cytokines such as IL-10 and IL-4 were reported in previous studies [47–49].

Moreover, the changes of cytokines may produce behavioral changes by indoleamine 2,3-dioxygenase (IDO), which leads to a reduction of tryptophan [50]. As tryptophan is a precursor of 5-HT, the depletion of tryptophan would lead to a reduction of 5-HT. Previous efforts showing that the level of 5-HT significantly decreased in patients with depression compared to healthy controls support this finding [21]. The findings from our review are also in line with this conclusion. As the mechanism between depression and the immune system is still unclear, more studies are needed to explore underlying pathways.

Third, the negative feedback loop of the hippocampus has recently received intensive attention in studies on depression. Glucocorticoid receptors in the hippocampus are widely reported by researchers, and studies have found that the released glucocorticoid triggers a negative feedback with the hippocampus, which leads to a decreased amount of neuronal cells and eventually the hypoactivity of the hippocampus [51, 52]. Current findings with neuroimaging measurements support this possible pathway. A study by Duan et al. [53] found statistical improvement in the ratio of N-acetyl-aspartate/creatine (NAA/Cr) in the hippocampus after acupuncture interventions compared to pretreatment, which indicated that acupuncture may improve depressive syndromes by decreasing the level of cortisol and activating the activity of the hippocampus (Figure 4). Although neuroimaging studies show some beneficial effects in patients with depression after acupuncture interventions, valid conclusion cannot be drawn at this stage due to the small number of available studies. Further studies are needed to assess the changes in brain function through neuroimaging techniques.

Evidence-Based Complementary and Alternative Medicine

This systematic review and meta-analysis has several limitations. First, due to great variation in neuroscience outcomes across eligible studies and the minimal number of studies in each outcome, a meta-analysis to synthesize neurological effects for MDD in the present review was not performed. Second, most of the selected studies used inadequate allocation concealment. Participants knew whether they were in the experiment or control groups even though a randomization procedure was used. Such insufficient concealment might generate subjectivity and expectation biases. Third, blinding of the intervention in many studies was absent. This might lead to an overestimation of the treatment benefits of NTCT for MDD. Fourth, because only two studies reported a followup period, meta-analysis to investigate the long-term effects of NTCT for MDD was not conducted. Fifth, the publication language was limited to Chinese and English. It is possible that we have missed studies published in journals of other languages.

5. Conclusion

In conclusion, this systematic review and meta-analysis has demonstrated that acupuncture-medication interventions produce more benefits than medication for improving depressive symptoms. The mechanisms by which acupuncture leads to positive responses for MDD might be based on the following three pathways: (1) HPA axis, (2) LCimmunity pathway, and (3) negative feedback loop of the hippocampus. Few peer-reviewed articles reported on the neurological effects of NTCT in either Chinese or English language before 2007.

Given the available NTCT options in this review, the results of traditional Chinese exercise such as Qigong and Tai Chi are inconclusive. It is difficult to summarize the current findings and propose the possible mechanisms in understanding how the body reacts when patients practice traditional Chinese exercise because the number of studies reporting neurological effects is limited. Future studies, with well-designed RCTs, should be conducted to investigate the neurological aspects of traditional Chinese mind-body exercise on MDD. Meanwhile, a cross-sectional study is needed to test the proposed plausible pathways.

Appendix

Search Terms

#1 depression
#2 major depressive disorder
#3 depressed mood
#4 mood disorder
#5 affective disorder
#6 dysthymia
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 neuroscience
#9 EEG

#10 blood sample #11 endocrine #12 neurological pathway #13 neuroanatom * #14 neuroimag* #15 neurotransmitter #16 scientific basis #17 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 #18 massage #19 complementary therapies #20 musculoskeletal manipulations #21 traditional medicine #22 East Asian traditional medicine #23 acupuncture #24 Qigong #25 mind-body therapies #26 breathing exercises #27 Tai Chi #28 Baduanjin #29 #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 #30 adults #31 human #32 #30 OR #31 #33 #7 AND #17 AND #29 AND #32

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Jiajia Ye searched for articles, assessed the quality of the included trials, and wrote the draft version of the manuscript. Wai Ming Cheung searched for articles and assessed the quality of the included trials. Hector Wing Hong Tsang made a decision when there was a disagreement and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors would like to thank Dr. Raymond Chung and Prof. David Man for their comments on this meta-analysis. Also, the authors would like to thank Ms. Wendy So and Ms. Duo Ye for their help in data extraction and figures modification.

References

- A. J. Ferrari, F. J. Charlson, R. E. Norman et al., "Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010," *PLoS Medicine*, vol. 10, no. 11, article e1001547, 2013.
- [2] W. H. Organization, World Health Organization Depression Fact sheet No 369.(2012), 2018.
- [3] L. Andrade, J. J. Caraveo-Anduaga, P. Berglund et al., "The epidemiology of major depressive episodes: results from the international consortium of psychiatric epidemiology (ICPE) surveys," *International Journal of Methods in Psychiatric Research*, vol. 12, no. 1, pp. 3–21, 2003.
- [4] R. C. Kessler, K. A. McGonagle, S. Zhao et al., "Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey," *Archives of General Psychiatry*, vol. 51, no. 1, pp. 8–19, 1994.
- [5] S. Lee, A. Tsang, and K. Kwok, "Twelve-month prevalence, correlates, and treatment preference of adults with DSM-IV major depressive episode in Hong Kong," *Journal of Affective Disorders*, vol. 98, no. 1-2, pp. 129–136, 2007.
- [6] A. American Psychiatric and D. S. M. T. F. American Psychiatric Association, *Diagnostic and Statistical Manual of Mental Dis*orders (DSM-5), American Psychiatric Association, Arlington, VA, USA, 5th edition, 2013.
- [7] K. N. Fountoulakis and H.-J. Möller, "Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data," *The International Journal of Neuropsychopharmacology*, vol. 14, no. 3, pp. 405–412, 2011.
- [8] J. H. Wright, J. J. Owen, D. Richards et al., "Computer-assisted cognitive-behavior therapy for depression: a systematic review and meta-analysis," *Journal of Clinical Psychiatry*, vol. 80, no. 2, 2019.
- [9] S. M. Arnfred, R. Aharoni, M. Hvenegaard et al., "Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial," *BMC Psychiatry*, vol. 17, no. 1, article 37, 2017.
- [10] B. N. Renn and P. A. Areán, "Psychosocial treatment options for major depressive disorder in older adults," *Current Treatment Options in Psychiatry*, vol. 4, no. 1, pp. 1–12, 2017.
- [11] S.-G. Zhou, Y.-F. Hou, D. Liu, and X.-Y. Zhang, "Effect of cognitive behavioral therapy versus interpersonal psychotherapy in patients with major depressive disorder: a meta-analysis of randomized controlled trials," *Chinese Medical Journal*, vol. 130, no. 23, pp. 2844–2851, 2017.
- [12] W.-Y. Jiang, "Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science," *Trends in Pharmacological Sciences*, vol. 26, no. 11, pp. 558–563, 2005.
- [13] X. Cheng, D.-M. Wang, X. Chen et al., "Health Qigong Wuqinxi improves hydrogen proton magnetic resonance spectra in prefrontal cortex and hippocampus in college students with mild depression," *Journal of Southern Medical University*, vol. 36, no. 11, pp. 1468–1476, 2016.
- [14] H. Luo, F. Meng, Y. Jia, and X. Zhao, "Clinical research on the therapeutic effect of the electro-acupuncture treatment in patients with depression," *Psychiatry and Clinical Neurosciences*, vol. 52, no. S6, pp. S338–S340, 1998.
- [15] X. Wang, Z. Wang, J. Liu et al., "Repeated acupuncture treatments modulate amygdala resting state functional connectivity of depressive patients," *NeuroImage: Clinical*, vol. 12, pp. 746– 752, 2016.

- [16] Z. Wang, X. Wang, J. Liu et al., "Acupuncture treatment modulates the corticostriatal reward circuitry in major depressive disorder," *Journal of Psychiatric Research*, vol. 84, pp. 18–26, 2017.
- [17] Z. Zhang, L. Zhang, G. Zhang, J. Jin, and Z. Zheng, "The effect of CBT and its modifications for relapse prevention in major depressive disorder: a systematic review and meta-analysis," *BMC Psychiatry*, vol. 18, no. 1, article 50, 2018.
- [18] S. Lee and S. Lim, "Clinical effectiveness of acupuncture on Parkinson disease: a PRISMA-compliant systematic review and meta-analysis," *Medicine (Baltimore)*, vol. 96, no. 3, article e5836, 2017.
- [19] Y. Yang, W. Q. Qiu, Y. L. Hao et al., "The efficacy of traditional chinese medical exercise for parkinson's disease: a systematic review and meta-analysis," *PLoS ONE*, vol. 10, no. 4, article e0122469, 2015.
- [20] L. Zou, A. Yeung, X. Quan, S. D. Boyden, and H. Wang, "A systematic review and meta-analysis of mindfulness-based (Baduanjin) exercise for alleviating musculoskeletal pain and improving sleep quality in people with chronic diseases," *International Journal of Environmental Research and Public Health*, vol. 15, no. 2, 2018.
- [21] Y. Liu, H. Feng, H. Mao et al., "Impact on serum 5-HT and TH1/TH2 in patients of depressive disorder at acute stage treated with acupuncture and western medication," *Chinese Acupuncture & Moxibustion*, vol. 35, no. 6, pp. 539–543, 2015.
- [22] W. J. Z. Wenxian, W. Qunsong, J. Xiangdong, and Y. Guozhen, "Antidepressant effect of acupuncture and its influence on peripheral inflammatory cytokines," *Journal of Traditional Chinese Medicine*, vol. 28, no. 8, pp. 816–819, 2017.
- [23] W. J. Z. Wenxian, W. Qunsong, J. Xiangdong, and Y. Guozhen, "Effect of acupuncture on the autonomic nervous system in patients with major depressive disorder," *Lishizhen Medicine* and Materia Medica Research, vol. 29, no. 2, pp. 381–383, 2018.
- [24] L. Zhuo, "Clinical observation of fuzi xiaoyao san combined with acupuncture in treating MDD patients with syndrome of liver-qi stagnation," *Journal of New Chinese Medicine*, vol. 49, no. 9, pp. 128–130, 2017.
- [25] A. S. Chan, Y. M. Y. Han, S. L. Sze, Q. Y. Wong, and M.-C. Cheung, "A randomized controlled neurophysiological study of a Chinese Chan -based mind-body intervention in patients with major depressive disorder," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 812096, 12 pages, 2013.
- [26] Y. Song, D. Zhou, J. Fan, H. Luo, and U. Halbreich, "Effects of electroacupuncture and fluoxetine on the density of GTPbinding-proteins in platelet membrane in patients with major depressive disorder," *Journal of Affective Disorders*, vol. 98, no. 3, pp. 253–257, 2007.
- [27] H. W. H. Tsang, W. W. N. Tsang, A. Y. M. Jones et al., "Psychophysical and neurophysiological effects of qigong on depressed elders with chronic illness," *Aging & Mental Health*, vol. 17, no. 3, pp. 336–348, 2013.
- [28] C. Song, U. Halbreich, C. Han, B. E. Leonard, and H. Luo, "Imbalance between Pro- and Anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment," *Pharmacopsychiatry*, vol. 42, no. 5, pp. 182–188, 2009.
- [29] R. D. Vázquez, L. González-Macías, C. Berlanga, and F. J. Aedo, "Effect of acupuncture treatment on depression: Correlation between psychological outcomes and salivary cortisol levels," *Salud mental*, vol. 34, no. 1, pp. 21–26, 2011.
- [30] H. Lavretsky, L. L. Alstein, R. E. Olmstead et al., "Complementary use of Tai Chi Chih augments escitalopram treatment

of geriatric depression: a randomized controlled trial," *The American Journal of Geriatric Psychiatry*, vol. 19, no. 10, pp. 839–850, 2011.

- [31] H. W. Tsang, W. W. Tsang, A. Y. Jones et al., "Psycho-physical and neurophysiological effects of qigong on depressed elders with chronic illness," *Aging & mental health*, vol. 17, no. 3, pp. 336–348, 2013.
- [32] R.-Z. Kou, H. Chen, M.-L. Yu, T.-C. Xu, S.-P. Fu, and S.-F. Lu, "Acupuncture for behavioral changes of experimental depressive disorder: a systematic review and meta-analysis," *Scientific Reports*, vol. 7, no. 1, article 9669, 2017.
- [33] H. MacPherson, A. Vickers, M. Bland et al., "Acupuncture for chronic pain and depression in primary care: a programme of research," *Programme Grants for Applied Research*, pp. 1–342, 2017.
- [34] A. Steiger, "Neurochemical regulation of sleep," *Journal of Psychiatric Research*, vol. 41, no. 7, pp. 537–552, 2007.
- [35] E. Dziurkowska, M. Wesolowski, and M. Dziurkowski, "Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy," *Archives of Women's Mental Health*, vol. 16, no. 2, pp. 139–147, 2013.
- [36] P. M. Plotsky, M. J. Owens, and C. B. Nemeroff, "Psychoneuroendocrinology of depression: hypothalamicpituitary-adrenal axis," *Psychiatric Clinics of North America*, vol. 21, no. 2, pp. 293–307, 1998.
- [37] S. Suzuki and C. Tobe, "Effect of acupressure, acupuncture and moxibustion in women with pregnancy-related anxiety and previous depression: a preliminary study," *Journal of Clinical Medicine Research*, vol. 9, no. 6, pp. 525–527, 2017.
- [38] D. Rhebergen, N. C. M. Korten, B. W. J. H. Penninx et al., "Hypothalamic-pituitary-adrenal axis activity in older persons with and without a depressive disorder," *Psychoneuroendocrinology*, vol. 51, pp. 341–350, 2015.
- [39] J. Ye, S. Cai, W. M. Cheung, and H. W. Tsang, "An east meets west approach to the understanding of emotion dysregulation in depression: from perspective to scientific evidence," *Frontiers in Psychology*, vol. 10, article 574, 2019.
- [40] T. B. Herbert and S. Cohen, "Depression and immunity: a metaanalytic review," *Psychological Bulletin*, vol. 113, no. 3, pp. 472– 486, 1993.
- [41] I. Damjanov, *Pathophysiology*, Saunders/Elsevier, Philadelphia, Pa, USA, 2009.
- [42] G. Haskó and C. Szabó, "Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system," *Biochemical Pharmacology*, vol. 56, no. 9, pp. 1079–1087, 1998.
- [43] R. Bertini, S. Garattini, R. Delgado, and P. Ghezzi, "Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice," *The Journal* of *Immunology*, vol. 79, no. 2, pp. 217–219, 1993.
- [44] G. P. Chrousos, "The stress response and immune function: clinical implications: the 1999 Novera H. Spector lecture," *Annals of the New York Academy of Sciences*, vol. 917, pp. 38–67, 2000.
- [45] R. N. Spengler, S. W. Chensue, D. A. Giacherio, N. Blenk, and S. L. Kunkel, "Endogenous norepinephrine regulates tumor necrosis factor-α production from macrophages in vitro," *The Journal of Immunology*, vol. 152, no. 6, pp. 3024–3031, 1994.
- [46] E. Won and Y.-K. Kim, "Stress, the autonomic nervous system, and the immune-kynurenine pathway in the etiology of depression," *Current Neuropharmacology*, vol. 14, no. 7, pp. 665–673, 2016.

- [47] F. S. Dhabhar, H. M. Burke, E. S. Epel et al., "Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression," *Journal of Psychiatric Research*, vol. 43, no. 11, pp. 962–969, 2009.
- [48] P. C. Strike, J. Wardle, and A. Steptoe, "Mild acute inflammatory stimulation induces transient negative mood," *Journal of Psychosomatic Research*, vol. 57, no. 2, pp. 189–194, 2004.
- [49] C. E. Wright, P. C. Strike, L. Brydon, and A. Steptoe, "Acute inflammation and negative mood: mediation by cytokine activation," *Brain, Behavior, and Immunity*, vol. 19, no. 4, pp. 345– 350, 2005.
- [50] J. C. Felger and F. E. Lotrich, "Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications," *Neuroscience*, vol. 246, pp. 199–229, 2013.
- [51] S. Campbell and G. MacQueen, "The role of the hippocampus in the pathophysiology of major depression," *Journal of Psychiatry* & *Neuroscience*, vol. 29, no. 6, pp. 417–426, 2004.
- [52] X. Wang and J. Yan, "Morphological changes of hippocampal neurons in the condition of elevated plasma glucocorticoid," *Journal of Anatomy*, vol. 14, no. 4, pp. 330–333, 1991.
- [53] D.-M. Duan, Y. Tu, S. Jiao, and W. Qin, "The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with fluoxetine intervention—a randomized, controlled trial," *Chinese Journal of Integrative Medicine*, vol. 17, no. 3, pp. 190–199, 2011.